Dynavax with new HEPLISAV Data (NASDAQ:DVAX)
Source: http://feedproxy.google.com/~r/FavStocks/~3/4NZ-xPwe4W4/Posted on Friday, October 30th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data will be presented publicly in a poster session on Saturday, October 31, 2009 at the Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania.
Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops product candidates like Toll-like Receptor also known as TLR. HEPLISAV is a Phase 3 adult hepatitis B vaccine that provides increased and rapid protection to the patients with fewer doses compare to the current licensed vaccines available in the market. During the Phase 3 trial of HEPLISAV around 2500 individuals were vaccinated with HEPLISAV and the vaccine demonstrated that it is safe and well tolerated. The total worldwide market for adult hepatitis B vaccines is growing and Dynavax is clearly looking forward to expand their business at the same time provide chronic kidney disease patients some kind of vaccine that can provide rapid and increase protection.
Those chronic kidney disease patients who were vaccinated with HEPLISAV demonstrated rapid and increased protection against hepatitis B viral infection in fewer doses. And around 96 percent of the patients vaccinated with HEPLISAV achieved seroprotection within 7 months. On the other hand patients who were receiving Engerix-B received more doses in order to reach seroprotection within 7 months of trial period. Many vaccine investigators are also happy with the results of HEPLISAV and have praised it saying that HEPLISAV provides faster and superior immunogenicity with fewer doses.
Last 5 posts by Jyotsna Ramani
- ImmunoGen’s Second License to Amgen (IMGN, AMGN) - November 20th, 2009
- Sucampo Granted Marketing Authorization From FDA (NASDAQ:SCMP) - November 20th, 2009
- Exelixis PI3K Interim Data (NASDAQ:EXEL) - November 18th, 2009
- ImmunoGen Announces IMGN901 Data (NASDAQ:IMGN) - November 18th, 2009
- ArQule’s Drug Discovery Platform (NASDAQ:ARQL) - November 17th, 2009
America, Biopharmaceutical, Biotech, chronic kidney disease;, Dynavax Technologies Corporation, FavStocks, Hepatitis B;, Infectious Disease Society of America, Investing Lessons, Pennsylvania, Philadelphia, Stocks to Watch, Vaccines, viral infection
 About Jyotsna Ramani (http://www.favstocks.com)
Joyotsna has completed Post Graduation in Tourism from College of Vocational Studies apart from a full time MBA degree in Finance. She has worked with several reputed companies including IBM. Currently, she is a SAHM, earning a living off trading in the stock market and forex. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.